Global cytokine analysis in myeloproliferative disorders

Leukemia Research

Volumn 31, Issue 10, 2007, Pages 1389-1392

  Ho, Ching Liang ^a,b   Lasho, Terra L ^a   Butterfield, Joseph H ^a   Tefferi, Ayalew ^a  

^a MAYO CLINIC   (United States)

^b TRI SERVICE GENERAL HOSPITAL   (Taiwan)

Author keywords

Bone marrow stroma; Cytokine array; Myelofibrosis; Pathogenesis

Indexed keywords

CYTOKINE; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; SOMATOMEDIN BINDING PROTEIN 2; TISSUE INHIBITOR OF METALLOPROTEINASE 1;

ARTICLE; CHEMOLUMINESCENCE; CLINICAL ARTICLE; CYTOKINE PRODUCTION; ENZYME LINKED IMMUNOSORBENT ASSAY; EVALUATION; HIGH THROUGHPUT SCREENING; HUMAN; MYELOID METAPLASIA; MYELOPROLIFERATIVE DISORDER; PATHOGENESIS; POLYCYTHEMIA VERA; PRIORITY JOURNAL; PROTEIN FUNCTION; QUANTITATIVE ASSAY;

CHEMOKINE CCL4; CYTOKINES; HUMANS; IMMUNOLOGIC TECHNIQUES; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 2; MYELOPROLIFERATIVE DISORDERS; TISSUE INHIBITOR OF METALLOPROTEINASE-1; UP-REGULATION;

EID: 34547686254     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2006.12.024     Document Type: Article

References (24)

1. Tefferi A. The Philadelphia chromosome negative chronic myeloproliferative disorders: a practical overview. Mayo Clin Proc 73 (1998) 1177-1184
2. Tefferi A. The pathogenesis of chronic myeloproliferative diseases. Int J Hematol 73 (2001) 170-176
3. Bench A.J., Cross N.C., Huntly B.J., Nacheva E.P., and Green A.R. Myeloproliferative disorders. Bailliere's Best Pract Rev Clin Hematol 14 (2001) 531-551
4. Tefferi A. Chronic myeloid disorders: classification and treatment overview. Semin Hematol 38 (2001) 1-4
5. Murate T., Yamashita K., Isogai C., Suzuki H., Ichihara M., Hatano S., et al. The production of tissue inhibitors of metalloproteinases (TIMPs) in megakaryopoiesis: possible role of platelet- and megakaryocyte-derived TIMPs in bone marrow fibrosis. Br J Haematol 99 (1997) 181-189
6. Musolino C., Calabro L., Bellomo G., Martello F., Loteta B., Pezzano C., et al. Soluble angiogenic factors: implications for chronic myeloproliferative disorders. Am J Hematol 69 (2002) 159-163
7. Wang J.C., Novetsky A., Chen C., and Novetsky A.D. Plasma matrix metalloproteinase and tissue inhibitor of metalloproteinase in patients with agnogenic myeloid metaplasia or idiopathic primary myelofibrosis. Br J Haematol 119 (2002) 709-712
8. Hermouet S., Godard A., Pineau D., Corre I., Raher S., Lippert E., et al. Abnormal production of interleukin (IL)-11 and IL-8 in polycythaemia vera. Cytokine 20 (2002) 178-183
9. Jensen M.K., Holten-Andersen M.N., Riisbro R., de Nully Brown P., Larsen M.B., Kjeldsen L., et al. Elevated plasma levels of TIMP-1 correlate with plasma suPAR/uPA in patients with chronic myeloproliferative disorders. Eur J Haematol 71 (2003) 377-384
10. Dranoff G. Cytokines in cancer pathogenesis and cancer therapy. Nat Rev Cancer 4 (2004) 11-22
11. Huang R.P. Detection of multiple proteins in an antibody-based protein microarray system. J Immunol Methods 255 (2001) 1-13
12. Szodoray P., Alex P., Brun J.G., Centola M., and Jonsson R. Circulating cytokines in primary Sjogren's syndrome determined by a multiplex cytokine array system. Scand J Immunol 59 (2004) 592-599
13. Huang R.P., Huang R., Fan Y., and Lin Y. Simultaneous detection of multiple cytokines from conditioned media and patient's sera by an antibody-based protein array system. Anal Biochem 294 (2001) 55-62
14. Lin Y., Huang R., Cao X., Wang S.M., Shi Q., and Huang R.P. Detection of multiple cytokines by protein arrays from cell lysate and tissue lysate. Clin Chem Lab Med 41 (2003) 139-145
15. Yoon S.Y., Li C.Y., Lloyd R.V., and Tefferi A. Bone marrow histochemical studies of fibrogenic cytokines and their receptors in myelodysplastic syndrome with myelofibrosis and related disorders. Int J Hematol 72 (2000) 337-342
16. Yoon S.Y., Tefferi A., and Li C.Y. Bone marrow stromal cell distribution of basic fibroblast growth factor in chronic myeloid disorders. Haematologica 86 (2001) 52-57
17. Baker A.H., Edwards D.R., and Murphy G. Metalloproteinase inhibitors: biological actions and therapeutic opportunities. J Cell Sci 115 (2002) 3719-3727
18. Michl P., Spoettl G., Engelhardt D., and Weber M.M. Alterations of the insulin-like growth factor system in patients with polycythemia vera. Mol Cell Endocrinol 181 (2001) 189-197
19. Mirza A.M., Ezzat S., and Axelrad A.A. Insulin-like growth factor binding protein-1 is elevated in patients with polycythemia vera and stimulates erythroid burst formation. Blood 89 (1997) 1862-1869
20. Correa P.N., Eskinazi D., and Axelrad A.A. Circulating erythroid progenitors in polycythemia vera are hypersensitive to insulin-like growth factor-1 in vitro: studies in an improved serum-free medium. Blood 83 (1994) 99-112
21. Bock O., Tessema M., Serinsoz E., von Wasielewski R., Busche G., and Kreipe H. Aberrant expression of insulin-like growth factor-2 (IGF-2) in Philadelphia chromosome negative chronic myeloproliferative disorders. Leuk Res 28 (2004) 1145-1151
22. Wetterau L.A., Moore M.G., Lee K.W., Shim M.L., and Cohen P. Novel aspects of the insulin-like growth factor binding proteins. Mol Genet Metab 68 (1999) 161-181
23. Menten P., Wuyts A., and Van Damme J. Macrophage inflammatory protein-1. Cytokine Growth Factor Rev 13 (2002) 455-481
24. Titius B.R., Thiele J., Schaefer H., Kreipe H., and Fischer R. Ki-S1 and proliferating cell nuclear antigen expression of bone marrow macrophages. Immunohistochemical and morphometric study including reactive (inflammatory) myelitis, secondary aplastic anemia, AIDS, myelodysplastic syndromes and primary (idiopathic) osteomyelofibrosis. Acta Haematol 91 (1994) 144-149